Suspected cancer: recognition and referral (NG12)Product type:GuidanceProgramme:NICE guidelineLast updated: 1 May 2025Published: 23 June 2015
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)Product type:GuidanceProgramme:Clinical guidelineLast updated: 26 April 2023Published: 26 July 2010
Endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach (IPG717)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 2 March 2022
NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal) (TA745)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 November 2021
Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 8 February 2021Published: 24 February 2010
Entrectinib for treating NTRK fusion-positive solid tumours (TA644)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 August 2020
Mifamurtide for the treatment of osteosarcoma (TA235)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 October 2011
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 November 2010Published: 27 October 2004
Improving outcomes for people with sarcoma (CSG9)Product type:GuidanceProgramme:Cancer service guidelinePublished: 20 March 2006
Next-generation sequencing panel for solid tumour cancers in children (MIB133)Product type:AdviceProgramme:Medtech innovation briefingPublished: 8 January 2018
Suspected cancer (QS124)Product type:Quality standardLast updated: 5 December 2017Published: 30 June 2016
Suspected CancerStatus:In developmentProgramme:NICE guidelineExpected publication date: 13 March 2026
NY-ESO-1 T-cells for treating synovial sarcoma ID1286Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults [TSID10652]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC